TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05350488

Intervention type: OTHER
Intervention: Informational Interview
Description: Interview topics will fall in the broad categories of assessing medical knowledge and understanding of stroke, knowledge of medical and community resources, understanding and experience of post-stroke rehabilitation barriers faced upon reintegrating back home and ability to continue management of stroke diagnosis and suggestions for improvement.

Intervention type: OTHER
Intervention: Informational Interview
Description: Interview topics will fall in the broad categories of assessing medical knowledge and understanding of stroke, knowledge of medical and community resources, understanding and experience of post-stroke rehabilitation barriers faced upon reintegrating back home and ability to continue management of stroke diagnosis and suggestions for improvement.

Intervention type: OTHER
Intervention: Focus Group
Description: Focus group topics will fall into the same broad categories as the informational interviews, however will be asked from a caregiver's perspective
Study: NCT06337747

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional technique
Description: Subjects randomized to the traditional technique will receive 3cc of PLLA (per side, per treatment) in the anterior temporal region.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental technique
Description: Subjects randomized to the extended technique will receive 3cc of PLLA (per side, per treatment) in the anterior temporal region, as well as 2cc (per side, per treatment) in the posterior (i.e., behind the hairline) temporal region.
Study: NCT04901234

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radiotherapy +/- chemotherapy
Description: No radiotherapy adaptation unless major dosimetric deviation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental radiotherapy +/- chemotherapy
Description: Systemic MRI-based radiotherapy adaptation mid-treatment
Study: NCT05905250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an empirically supported protocol, further refined with evidence-based strategies
Description: The intervention utilizes an empirically supported protocol, further refined with evidence-based strategies targeting the needs of young adult (YA) survivors. Its long-term goal is to promote hopeful thinking, and ultimately enhance other long-term markers of quality of life (QOL) (including mental health and health behaviors). The intervention follows 8 weekly curricula, reinforced through psychoeducation and skill-building, homework/practical application, and self-monitoring. Its 8-week design was informed by cognitive behavioral therapy and positive psychology intervention literature.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Health education regarding maintaining a healthy weight, physical activity, and nutrition, based on American Cancer Society and NCI guidelines/recommendations.
Study: NCT05633589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sc610 cell injection
Description: Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell product preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and amplification factor, and cell quantity are amplified. The obtained Sc610 is used for one-time intravenous infusion.
Study: NCT06304402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Percussive Massage Treatment
Description: In the group where regional vibration is applied, the Hypervolt™ vibrating massage device (HYPERICE Inc, US) will be used. This device is a vibration device with five different speed settings, vibrating at 3,200 percussions per minute (HYPERICE Inc. 'Hypervolt' device. Retrieved from https://hyperice.com/hypervolt-bluetooth, Accessed on: 08.12.2021). The device offers five different head attachment options. For this study, the ball attachment option will be selected as it is the least aggressive option, and the vibration from the device will be applied to the relevant muscle body (Kayoda, 2019). For facilitatory effect, the application will be performed on the posterior deltoid for 5 minutes at a low frequency.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Proprioceptive Neuromuscular Facilitation Stretching
Description: Among the PNF stretching techniques, the muscle-relaxation technique will be applied. The athlete will be positioned in a side-lying posture on the treatment table with the dominant shoulder in the modified sleeper position, ensuring stabilization of the scapula on the table. The other arm will be positioned in extension along the body with the palm facing upwards. The participant will be instructed to actively bring the arm of the lower limb to the physiological barrier of internal rotation. At this point, they will be asked to perform maximum isometric contraction in external rotation for 7 seconds. After the isometric contraction, the muscle will be relaxed, and active-assisted stretching will be applied in internal rotation for 15 seconds. A 5-second rest will be provided between repetitions, and the exercise will consist of 5 repetitions.
Study: NCT06180083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine Hydrochloride/ Fluticasone propionate nasal spray
Description: A single dose \[four sprays (two sprays in each nostril)\] of Azelastine HCL/ Fluticasone Propionate 137 mcg/50 mcg Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine Hydrochloride/ Fluticasone propionate nasal spray
Description: A single dose \[four sprays (two sprays in each nostril)\] of Azelastine HCL/ Fluticasone Propionate 137 mcg/50 mcg Nasal Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 'DYMISTA' NASAL SPRAY
Description: A single dose \[four sprays (two sprays in each nostril)\] of 'DYMISTA' (AZELASTINE HYDROCHLORIDE/ FLUTICASONE PROPIONATE) NASAL SPRAY 137 Microgram/50 Microgram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 'DYMISTA' NASAL SPRAY
Description: A single dose \[four sprays (two sprays in each nostril)\] of 'DYMISTA' (AZELASTINE HYDROCHLORIDE/ FLUTICASONE PROPIONATE) NASAL SPRAY 137 Microgram/50 Microgram
Study: NCT05693324

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minority stress
Description: Intervention based on Cognitive Behavioural and Compassion Focused Treatments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minority stress
Description: Intervention based on Cognitive Behavioural and Compassion Focused Treatments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minority stress
Description: Intervention based on Cognitive Behavioural and Compassion Focused Treatments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minority stress
Description: Intervention based on Cognitive Behavioural and Compassion Focused Treatments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minority stress
Description: Intervention based on Cognitive Behavioural and Compassion Focused Treatments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minority stress
Description: Intervention based on Cognitive Behavioural and Compassion Focused Treatments
Study: NCT06323395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vizol S LIPID BALANCE eye drops
Description: 1 drop 4 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ophthalmic saline eye drops
Description: 1 drop 4 times a day
Study: NCT05054569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Stress Management and Health Education
Description: Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
Study: NCT06182436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: For the experimental treatment, the child will play with the VR device for five minutes prior to the subcutaneous injection to reduce pain. The VR game Dream and the Pico Neo 4 VR headset were designed by Paperplane Therapeutics for the pediatric population. Participants will be able to direct laser beams at magical elements such as trolls and crystals. Since it is a no-success game, participants can enjoy it regardless of their past video game experience.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard care consisting of injecting dupilumab subcutaneously without any distractive measure, with the child having full knowledge of the intervention.~Use of any co-interventions for pain management (music, comforting, child life specialist or other) during this sequence will be documented
Study: NCT06397209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propioceptive Neuromascular facilitation
Description: Propioceptive Neuromascular Facilitation techniques will be given for 5 days/week,10 repetitions,30 minutes/day for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neural Flossing
Description: Neural Flossing exercises will be given for 5 days/week, 3 sets of 10 repetitions in 2 minutes for 30 minutes for 8 weeks
Study: NCT04964167

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Plant extract
Description: Natural plant extract

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Plant extract
Description: Natural plant extract

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Plant extract
Description: Natural plant extract
Study: NCT00183508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Participants will learn cognitive behavioral strategies for symptom reduction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Participants will receive psychoeducation regarding common reactions to traumatic events
Study: NCT04825925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization)
Description: Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, the Platinum was infused. BAI (Bronchial Arterial Infusion ) chemotherapy was followed by DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with Vinorelbine were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
Study: NCT04939844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab, bortezomib, lenalidomide, dexamethason
Description: All participants will receive the same treatment as described under arm.
Study: NCT05430113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator (octopolar Medtronic Vectris Leads)
Description: 2-4 leads FDA-approved for treatment of symptoms of refractory pain
Study: NCT06364436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reiki energy therapy
Description: In order to perform distance Reiki application, the practitioner must have completed Reiki II level training according to the Traditional Usui Reiki system and must be attuned by a person with a Usui Reiki Master and Teacher degree. With harmony, the energy channels in the individual's body are opened and the harmonious individual becomes a tool of universal healing energy.
Study: NCT06543082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Description: Participants will take low-dose colchicine (0.6 mg once daily) in addition to ticagrelor maintenance therapy (90 mg twice daily), and discontinue aspirin the day after PCI. They will have an hs-CRP test 1 month after PCI. If the hs-CRP level is below 2 mg/L, colchicine will be discontinued 1 month after PCI. If it is 2 mg/L or higher, colchicine will be continued for 12 months after PCI.
Study: NCT05880225

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reciprocal Imitation Training
Description: As a naturalistic developmental behavioral intervention (NDBI), Reciprocal Imitation Training (RIT) utilizes contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music-enhanced Reciprocal Imitation Training
Description: Music-enhanced imitation training uses music and rhythm to enhance the predictability and salience of the strategies utilized within the Reciprocal Imitation Training platform (i.e., contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities).
Study: NCT05390385

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KE1 5g
Description: 5g of KE1 (KetoneAid, Falls Church, VA), diluted to 4 ounces

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KE1 10g
Description: 10g of KE1 (KetoneAid, Falls Church, VA), equal to 4 ounces

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KE4 5g
Description: 5g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces
Study: NCT05917132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritionnal intervention
Description: Participants will be provided with meals corresponding to each diet during the week. Participants will be required to eat only the meals provided.
Study: NCT06421987

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy (NIRS)
Description: NIRS is a portable, non-invasive, brain imaging device.
Study: NCT04647305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed face shield with Surgical face mask use
Description: Use of a closed face shield with a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and proper use of the closed face shield and the surgical face masks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical face mask use only
Description: Use of a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and the proper use of surgical face masks.
Study: NCT05749861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(5)
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(5)
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO
Study: NCT05874778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
Description: All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone) and conduct evaluation about treatment effects (i.e. efficacy evaluation) once every 2 cycles, and after their completion of the 6th cycle, they will receive maintenance treatment . After the end of 6th cycle of treatment or after their leaving the group, efficacy evaluation is conducted every three months to obtain relevant data regarding the 2-year Progression-Free Survival(PFS) and survival of the subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
Description: All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone) and conduct evaluation about treatment effects (i.e. efficacy evaluation) once every 2 cycles, and after their completion of the 6th cycle, they will receive maintenance treatment . After the end of 6th cycle of treatment or after their leaving the group, efficacy evaluation is conducted every three months to obtain relevant data regarding the 2-year Progression-Free Survival(PFS) and survival of the subjects.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy beyond standard R-CHOP Chemotherapy
Description: Radiotherapy: after completion of the standard R-CHOP treatment, enrolled patients will be divided into radiotherapy group and non-radiotherapy group. In radiotherapy group, further consolidation radiotherapy targeting patients' pre-treatment large masses or extranodal affected areas will be given, with routine segmentation of 30-36Gy/15-18f.
Study: NCT05057247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Duvelisib capsules should be swallowed whole with a glass of water (approximately 8 ounces).~Advise patients not to open, break, or chew the capsules. Duvelisib may be administered without regard to meals; however, subjects should avoid grapefruit and grapefruit juice while on duvelisib.~continue for up to 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel chemotherapy once every 21 days (by intravenous infusion) over about 30- 60 minutes at each visit. This will continue for up to 24 months
Study: NCT05703152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Exercise
Description: Therapeutic exercise program will be applied that will include two modalities: aerobic and resistance exercise. The duration will be 8 weeks with a frequency of 3 sessions per week, with a duration per session of 60 minutes.
Study: NCT06171035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D-printed high-fidelity craniofacial manikin model education
Description: Slide-based presention plus 3D printed model

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional model education
Description: Slide-based presention plus traditional model
Study: NCT05390385

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KE 10g
Description: 10g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Flavor-matched control placebo drink (KetoneAid, Falls Church, VA), 4 ounces
Study: NCT06324045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deprescribing
Description: 1. The clinical pharmacist will review the patient's medications using validated screening tools, draft a deprescribing plan of the potential problematic medications, consult with the physician (MDT-CKD nephrologist), make the needed amendments, and document in the medical records.~2. The plan will be implemented and monitored during the patient's appointments for 1- 2 weeks at the center by the nephrologist.~3. The medication plan will be reconciled before discharge from dialysis or a planned appointment, and patients will be given a deprescribing card containing medication information. A note will be posted on CERNER as well. The primary care physician might also be contacted by the MDT-CKD team for consultation or any inquiries regarding the patient's condition or medications.~4. The MDT-CKD specialist nurse will conduct 3 post-appointment follow-up phone calls on day 2, day 7, and day 28 to enquire about any withdrawal symptoms or any concerns of the patient.
Study: NCT05005299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is administered as an oral tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is administered as an oral tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is administered as an oral tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is administered as an oral tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is administered as an intravenous infusion at a dose of 30mg/m2 daily, to be administered over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is administered as an intravenous infusion at a dose of 30mg/m2 daily, to be administered over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is administered as an intravenous infusion at a dose of 30mg/m2 daily, to be administered over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is administered as an intravenous infusion at a dose of 30mg/m2 daily, to be administered over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered as an intravenous infusion at a dose of 750mg/m2 daily, to be administered over 30 minutes and to commence 1 hour after fludarabine infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered as an intravenous infusion at a dose of 750mg/m2 daily, to be administered over 30 minutes and to commence 1 hour after fludarabine infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered as an intravenous infusion at a dose of 750mg/m2 daily, to be administered over 30 minutes and to commence 1 hour after fludarabine infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered as an intravenous infusion at a dose of 750mg/m2 daily, to be administered over 30 minutes and to commence 1 hour after fludarabine infusion.
Study: NCT05435911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]
Description: Remimazolam Besylate is used as an intervention drug for general anesthesia, followed by flumazenil administration at the end of anesthesia, compared to propofol-based total intravenous anesthesia during breast cancer surgery under general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: Flumazenil is used as an additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is used as an active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during breast cancer surgery under general anesthesia.
Study: NCT04416932

Intervention type: PROCEDURE
Intervention: Ultasound
Description: Evaluation of post-operative patients who have had total shoulder arthroplasty and will assess the integrity of the rotator cuff using ultrasound.